Are target-family-privileged substructures truly privileged?

Journal of Medicinal Chemistry

Volumn 49, Issue 6, 2006, Pages 2000-2009

  Schnur, Dora M ^a   Hermsmeier, Mark A ^a   Tebben, Andrew J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR; ION CHANNEL; PROTEIN KINASE; SERINE PROTEINASE;

ANALYTIC METHOD; ARTICLE; CHANNEL GATING; GENE LIBRARY; PHARMACOPHORE; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN STRUCTURE; PROTEIN TARGETING; STRUCTURE ANALYSIS;

COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, FACTUAL; ION CHANNEL GATING; ION CHANNELS; LIGANDS; MOLECULAR STRUCTURE; PROTEIN KINASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; SERINE ENDOPEPTIDASES;

EID: 33645422011     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0502900     Document Type: Article

References (41)

1. Horton, D. A.; Bourne, G. T.; Smythe, M. L. The combinatorial synthesis of bicyclic privileged structure or privileged substructures. Chem. Rev. 2003, 103, 893-930.
2. Classpharmer is available from Bioreason, Inc., 3900 Paseo del Sol Santa Fe, NM 87507. http://bioreason.com/
3. Evans, B. E.; Rittle, K. E.; Bock, M. G.; Dipardo, R. M.; Freidinger, R. M.; Whiter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Methods for drug discovery-development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
4. Patchett, A.; Nargund, R. P. Privileged structures - an update. Annu. Rep. Med. Chem. 2000, 35, 289-298.
5. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39, 2887-2893.
6. Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudiniere, R. F. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J. Med. Chem. 1999, 42, 3251-3264.
7. th Mid Atlantic Regional Meeting of the American Chemical Society, Princeton, NJ, 2003.
8. Schnur, D. S.; Beno, B. R.; Good A.; Tebben, A.; Approaches to target class library design. In Chemoinformatics: Concepts, Methods and Tools for Drug Discovery, Methods in Molecular Biology; Bajorath, J., Ed.; Humana Press: Totowa, NJ, 2004; pp 355-377.
9. Lamb, M. L.; Bradley, E. K.; Beaton, G.; Bondy, S. S.; Castellino, A. J.; Gibbons, P. A.; Suto, M. J.; Grootenhuis, P. D. J. Design of a gene family screening library targeting G-protein coupled receptors. J. Mol. Graphics Modell. 2004, 23, 15-21.
10. Mueller, G. Medicinal chemistry of target family directed masterkeys. Drug Discovery Today 2003, 8, 681-691.
11. Bleicher, K. H.; Green, L. G.; Martin, R. E.; Rogers-Evans, M. Ligand identification for G-protein-coupled receptors: A lead generation perspective. Curr. Opin. Chem. Biol. 2004, 8, 287-296.
12. Merlot, C.; Domine, D.; Cleva, C.; Church, D. J. Chemical structures in drug discovery. Drug Discovery Today 2003, 8, 594-602.
13. Lowrie, J. F.; Delisle, R. K.; Hobbs, D. W.; Diller, D. J. The different strategies for designing GPCR and kinase targeted libraries. Comb. Chem. High Throughput Screening 2004, 7, 495-510.
14. Schuffenhauer, A.; Zimmermann, J.; Stoop, R.; van der Vyver, J.-J.; Lecchini, S.; Jacoby, E. An ontology for pharmaceutical ligands and its application for in silico screening and library design. J. Chem. Inf. Comput. Sci. 2002, 42, 947-955.
15. Aureus Pharmaceuticals, 174, Quai de Jemmapes, 75010 Paris, France; http://www.aureus-pharma.com.
16. Jubilant Biosys, Ltd., 8575 Window Latch Way, Columbia, MD 21045; http://www.jubilantbiosys.com.
17. Sertanty Inc., 1735 N. First St. #102, San Jose CA, 95112; http://www.sertanty.com.
18. Biowisdom Ltd., Babraham Hall, Babraham, Cambridge, CB2 4AT, United Kingdom; http://www.biowisdom.com/.
19. MDL Drug Data Report (MDDR) available from MDL Information Systems Inc., 14600 Catalina Street, San Leandro CA, 94577; http://www.mdl.com.
20. Compound structure file format, MDL Information Systems Inc., 14600 Catalina Street, San Leandro CA, 94577; http://www.mdl.com.
21. Chemicals directory available from from MDL Information Systems Inc., 14600 Catalina Street, San Leandro CA, 94577; http://www.mdl.com.
22. SYBYL available from Tripos, Inc., 1699 South Hanley Road, St. Louis, MO 63144-2319; http://www.tripos.com.
23. CombiLibMaker, developed by Pearlman et al., University of Texas at Austin, available as a module of SYBYL from Tripos, Inc., 1699 South Hanley Road, St. Louis, MO 63144-2319; http://www.tripos.com.
24. More recent and greatly improved versions for windows and linux are available as Optive Benchware from Optive Research, Inc., 12331-A Riata Trace Parkway, Suite 110, Austin, TX 78727; http://www.optive.com.
25. DiverseSolutions developed by Pearlman et al., University of Texas at Austin, available from Tripos, Inc., 1699 South Hanley Road, St. Louis, MO 63144-2319; http://www.tripos.com
26. or from Optive Research, Inc., 12331-A Riata Trace Parkway, Suite 110, Austin, TX 78727; http://www.optive.com.
27. Daylight Chemical Information Systems, Inc., 27401 Los Altos, Suite 360, Mission Viejo, CA 92691; http://www.daylight.com/.
28. SYBYL UNITY available from Tripos, Inc., 1699 South Hanley Road, St. Louis, MO 63144-2319; http://www.tripos.com.
29. Ashton, M.; Charlton, M. H.; Schwarz, M. K.; Thomas, R. J.; Whittaker, M.; The Selection and design of GPCR Ligands. Comb. Chem. High Throughput Screening 2004, 7, 441-452.
30. Aronov, A. M. Predictive in silico modeling for hERG channel blockers. Drug Discovery Today, 2005, 10, 149-155.
31. Fanelli, F.; DeBenedetti, P. G. Computational modeling approaches to structure-function analysis of G protein-coupled receptors. Chem. Rev. 2005, 9, 3297-3351.
32. Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. Privileged molecules for protein binding identified from NMR-based screening. J. Med. Chem. 2000, 43, 3443-3447.
33. Demuth, H. U. Recent developments in inhibiting cysteine and serine proteases. J. Enzyme Inhib. 1990, 3, 249-278.
34. Oshiro C.; Bradley E. K.; Eksterowicz J.; Evensen E.; Lamb M. L.; Lanctot J. K.; Putta S.; Stanton R.; Grootenhuis P. D. J. Performance of 3D-database molecular docking studies into homology models. J. Med. Chem. 2004, 47, 764-767.
35. Mueller, M. M.; Sperl, S.; Sturzebecher, J.; Bode, W.; Moroder, L. (R)-3-amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode. Biol. Chem. 2002, 383, 1185-1191.
36. Topliss, J. G. Some observations on classical QSAR. Perspect. Drug Discovery Des. 1993, 1, 253-268.
37. Kubinyi, H. 2D QSAR models: Hansch and Free-Wilson analyses. Comput. Med. Chem. Drug Discovery 2004, 539-570.
38. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
39. Bondensgaard, K.; Ankersen, M.; Thogersen, H.; Hansen, B. S.; Wulff, B. S.; Bywater, R. P. Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem. 2004, 47, 888-899.
40. Skiles, J. W.; Gonella, N. C.; Jeng, A. Y. The design, structure and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2001, 8, 425-474.
41. Pauls, H. W.; Ewing, W. R. The design of competitive, small-molecule inhibitors of coagulation factor Xa. Curr. Top. Med. Chem. 2001, 1, 83-100.